drugset / Trial / NCT02069730
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a study of select drug therapies in patients with salivary gland cancer. The study has two phases: a molecular profiling phase (phase 1) and a treatment phase (phase 2). Based on the Molecular profiling results in phase the participants will receive matched treatment if a specific aberration is identified or will receive treatment with Selinexor if unmatched and no druggable aberration is identified.
Timeline
- Start
- 2014-06
- Primary completion
- 2023-06
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 30 mg/m2 | Oral |